ACADIA Pharmaceuticals Inc. research snapshot
ACAD AI stock analysis currently reads ACADIA Pharmaceuticals Inc. as a commercial-stage CNS biopharma with two approved products (NUPLAZID for Parkinson's disease psychosis and DAYBUE for Rett syndrome), a strong cash position near $851 million, and a potential EU approval catalyst for DAYBUE after a positive CHMP opinion in July 2026. At the July 12, 2026 data cutoff, ACAD last closed near $26.22 with a market capitalization of about $4.49 billion. The TTM P/E of 11.86x appears low but reflects a trailing twelve-month net income that includes likely non-recurring items. The forward P/E of 78.12x gives a more realistic view of ongoing earning power. This page uses scenarios, technical levels, and source-backed facts. It is informational research, not investment advice.
Current price
$26.22
Market cap
$4.49 billion
AI score
63 / 100
Rating
Approved CNS franchise with a strong balance sheet, but uneven earnings quality and early pipeline limit conviction
Trend status
Moderate uptrend off Q1 2026 lows, approaching the 52-week high near $28.35
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | ACADIA sells two approved CNS drugs: NUPLAZID for Parkinson's disease psychosis and DAYBUE for Rett syndrome. Revenue is growing but comes from a narrow product base. | Medium-high |
| Moat | The moat comes from FDA-approved treatments in orphan/niche CNS indications where regulatory barriers, specialist relationships, and manufacturing know-how create moderate entry protection. DAYBUE has IP and orphan exclusivity until around 2030+ in the US. | Medium |
| Management | Management has built a commercial organization around two product launches and managed the DAYBUE approval and EU filing process. Insider selling was reported recently, which is a monitoring item. | Medium |
| Financial trend | Revenue has grown from about $604 million in FY2023 to roughly $1.1 billion TTM. GAAP profitability was achieved in the TTM period, but Q1 FY2026 net income was only $3.64 million, suggesting ongoing earnings quality varies by quarter. | Medium-high |
| Valuation | The trailing P/E of 11.86x is optically low but misleading due to one-time items. Forward P/E near 78.12x and P/S near 4.10x suggest a growth-dependent valuation. EV/Revenue of 3.37x is reasonable for a biotech with two marketed products. | Medium |
| Technical trend | ACAD has rallied from a Q1 2026 low near $19.69 toward the $28.35 52-week high. The stock is above its 50-day and 200-day moving averages but approaching overhead resistance. | Medium-high |
| Risk level | Key risks are NUPLAZID generic competition timing, DAYBUE EU commercial execution, narrow product concentration, early pipeline, insider selling, and the gap between TTM and normalized earnings. | Medium-high |
| AI confidence | Medium-high confidence for the balance sheet, cash, revenue, market cap math, and major risk categories. Lower confidence for normalized earnings power and forward P/E interpretation. | Medium-high data confidence |
| Investment certainty | Medium certainty. ACAD has products, cash, and a catalyst, but the valuation already prices in DAYBUE EU approval success, and the earnings base is uneven. | Medium |
ACAD AI stock forecast
The ACAD AI stock forecast uses scenario ranges around the $26.22 cutoff price. It does not claim that AI can predict a specific future price. The bullish case requires DAYBUE EU approval converting to meaningful revenue, NUPLAZID holding share, and pipeline progress. The base case assumes DAYBUE grows steadily while the market waits for normalized earnings clarity. The bearish case assumes NUPLAZID faces generic erosion or DAYBUE EU adoption disappoints.
$35 to $45
More likely if DAYBUE EU launch generates material revenue by late 2027, NUPLAZID holds market share, remlifanserin or ACP-211 produce positive Phase 2 data, and the market assigns a higher multiple to a multi-product CNS platform.
$24 to $30
More likely if DAYBUE grows at a moderate pace in the US and EU, NUPLAZID holds steady, the pipeline advances without binary events, and the stock trades at a P/S multiple between 3.5x and 5x on gradually improving revenue.
$16 to $22
More likely if NUPLAZID faces accelerated generic or branded competition, DAYBUE EU adoption falls short, pipeline trials produce negative data, or the forward multiple contracts as growth expectations reset.
ACAD AI technical analysis
ACAD AI technical analysis starts from the $26.22 July 10 close used for this July 12 static page. The stock has rallied from a March 2026 low near $19.69 and is testing the upper end of its 52-week range. Because this page does not fetch request-time market data, traders should confirm levels on a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $26.22 | Latest verified close used for this page as of the July 12, 2026 data cutoff. |
| Near support | $24.50 to $25.00 | Support planning zone around recent consolidation and the 50-day moving average area as reported by public technical sources. |
| Secondary support | $22.00 to $22.50 | The prior Q2 2026 pullback low area. A sustained break below this level would weaken the recovery setup. |
| Near resistance | $28.00 to $28.35 | The 52-week high zone. Breakout attempts need volume confirmation and preferably a catalyst catalyst like DAYBUE EU approval. |
| 50-day moving average | About $24.50 to $25.00 | Public technical sources showed ACAD above the 50-day moving average around the cutoff, supporting the near-term trend. |
| 200-day moving average | About $23.00 to $23.50 | ACAD was above its 200-day moving average, confirming a medium-term positive trend from the early 2026 lows. |
| Momentum | RSI near 58 to 62, trending up | RSI was in neutral-to-bullish territory after the rally from the 52-week low, not yet overbought. |
| Volume | About 1.37 million shares (July 10) | Volume was below the 1.72 million average, so a catalyst-driven move should be confirmed by above-average participation. |
| Volatility | ATR 14 near $1.20 to $1.50 | Position sizing should allow for normal daily movement of 4% to 6% around the cutoff price. |
| Invalidation | Close below $24.50, then $23.00 | A close below the 50-day area weakens the near-term momentum. A sustained break below the 200-day area would challenge the medium-term recovery trend. |
ACAD AI trading strategy
The ACAD AI trading strategy is a rules-based framework, not personalized advice. It combines product-catalyst evidence, technical confirmation, position sizing, and clear invalidation levels.
Look for ACAD to break above $28.35 with above-average volume and positive DAYBUE or pipeline news before treating the breakout as high conviction.
A failed breakout or daily close below the 50-day area at $24.50 should reduce confidence in continuation.
If ACAD pulls back toward $24.50 to $25.00 without a negative product or regulatory change, compare price stabilization with DAYBUE EU launch updates and quarterly revenue trajectory.
Do not average down solely because the balance sheet is strong. Define maximum loss and review pipeline timelines.
Track DAYBUE EU approval decision (CHMP positive, EC decision pending), quarterly NUPLAZID and DAYBUE revenue, pipeline Phase 2 data readouts, and insider trading patterns.
Reduce exposure if NUPLAZID revenue declines sequentially for two quarters or if DAYBUE EU launch faces pricing/reimbursement delays.
Investment research summary
ACADIA discovers and commercializes CNS drugs for neurological and rare diseases, currently selling NUPLAZID for Parkinson's disease psychosis and DAYBUE for Rett syndrome.
The moat is moderate and product-specific: FDA orphan designations give DAYBUE market exclusivity in Rett syndrome, while NUPLAZID benefits from specialist relationships and being the only approved drug for Parkinson's disease psychosis. Neither indication has high-volume generic competition today, but the IP position and exclusivity timeline need monitoring.
The thesis can fail if NUPLAZID loses exclusivity sooner than expected, DAYBUE EU adoption is slow or poorly reimbursed, the pipeline fails to deliver Phase 2 proof-of-concept, or the company uses its cash pile on dilutive acquisitions. The gap between TTM and forward earnings also creates a risk that the stock re-rates downward if normalized earnings are significantly below the TTM level.
The management team has executed two product launches (NUPLAZID and DAYBUE) and secured the CHMP positive opinion for DAYBUE in Europe. Recent insider selling is a monitoring signal. The CEO and leadership face a capital allocation decision as the company generates cash and must decide between pipeline investment, M&A, or returning capital to shareholders.
CNS drug development remains a high-need area with significant unmet medical demand. Conditions like Alzheimer's disease psychosis, Rett syndrome, and major depressive disorder have large addressable populations or high per-patient value. The trend is favorable for CNS-specialized biopharma, but clinical risk is high and regulatory hurdles are significant.
At the $26.22 cutoff price, ACAD trades at about 11.86x TTM P/E (misleading due to non-recurring items), 78.12x forward P/E, and 4.10x P/S. The low trailing multiple is not a reliable value signal. The stock prices in DAYBUE growth and EU approval but leaves limited room for pipeline or competitive disappointment.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| ACAD price | $26.22 close on July 10, 2026 | Yahoo Finance | July 12, 2026 |
| Market capitalization | $4.49 billion, verified as $26.22 x 171.2 million shares | financial_rigor.py market cap verification | July 12, 2026 |
| TTM revenue | $1.10 billion | Yahoo Finance and StockAnalysis | July 12, 2026 |
| TTM net income | $375.65 million (includes likely non-recurring items) | Yahoo Finance | July 12, 2026 |
| Q1 FY2026 revenue | $268.06 million | Yahoo Finance earnings data | July 12, 2026 |
| Q1 FY2026 net income | $3.64 million | Yahoo Finance earnings data | July 12, 2026 |
| Cash and cash equivalents | $851.46 million at most recent quarter | Yahoo Finance balance sheet data | July 12, 2026 |
| Total debt | Debt/Equity ratio of 4.07%, minimal debt | Yahoo Finance statistics | July 12, 2026 |
| TTM free cash flow | $154.14 million levered FCF | Yahoo Finance cash flow data | July 12, 2026 |
| Valuation math | 11.86x TTM P/E, 78.12x forward P/E, 4.10x P/S, 3.37x EV/Revenue, 29.13x P/FCF from financial_rigor.py | financial_rigor.py valuation verification | July 12, 2026 |
| 52-week price range | $19.69 to $28.35 | Yahoo Finance statistics | July 12, 2026 |
| Moving averages and momentum | 50-day MA about $24.50 to $25.00, 200-day MA about $23.00 to $23.50, RSI near 58 to 62 | Public technical snapshots and price range analysis | July 12, 2026 |
This ACAD AI stock analysis is an informational tool for research and education only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of July 12, 2026 and can be wrong. The forward P/E and TTM P/E gap highlights the uncertainty in normalized earnings estimates.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
